Luminex Corporation (NASDAQ:LMNX) will be discussing 2Q20 financial results with the investment community.on 4th August 2020 at 5:00 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.luminexcorp.com
Earnings Expectation
Luminex Corporation is reporting second quarter earnings results on Tuesday 4th August 2020, after market close. The consensus estimates from Thomson Reuters are income of $ 0.08 per share. For the full year, analysts predict revenues of $ 386.99 million, while looking forward to income of $ 0.21 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 352.00 million ~ $ 362.00 million
Click Here For More Historical Outlooks Of Luminex Corporation
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism.
